Dr Mark Gumbleton - BPharm MSc PhD MRPharmS
Following undergraduate studies in Pharmacy and completion of professional registration, Dr Gumbleton undertook postgraduate studies and fellowships in Clinical Pharmacology and Biopharmaceutics at the University of Aberdeen Medical School, School of Pharmacy Cardiff University and the Medical Centre at the University of California-San Francisco. After this he was appointed to the academic staff at the Universities of Strathclyde and Glasgow, before returning to Cardiff where he currently holds a Readership appointment.
His research activities include understanding at the whole body, tissue, cellular and molecular levels the interaction of drugs and delivery systems with biological barriers, particularly the barriers represented by lung epithelium and the blood-Brain-Barrier. In experimental therapeutics Dr Gumbleton has a particular interest cancer therapeutics. Current research also involves application of proteomic - Phage display library technologies to generate novel polymer peptide/protein conjugates for drug targeting, drug and solute biosensing, and as therapeutic agents in their right.
Dr Gumbleton is currently Executive Editor for Advanced Drug Delivery Reviews, a journal publishing high quality thematic reviews on a wide range of Advanced Drug Delivery topics. Dr Gumbleton is also on the editorial board of the Journal of Drug Targeting and International Journal of Nanomedicine. He has published over 90 full-length peer reviewed research publications; 20 journal series, authored textbook chapters or edited books; 116 conference abstracts or editorials; supervised 25 successful Ph.D. students and some 24 postdoctoral/visiting scientists. He has also served on a number of pan-European scientific steering committees in drug delivery and as organiser/ scientific programme organiser for International scientific meetings. Dr Gumbleton serves as consultant to pharmaceutial Industry in USA and UK and is Deputy Head of the Welsh School of Pharmacy Cardiff University.